Loading...
•
Sep 30, 2024
Essa Pharma Q4 2024 Earnings Report
ESSA Pharma reported financial results for the fourth quarter and fiscal year ended September 30, 2024, and initiated a process to explore strategic options.
Key Takeaways
ESSA Pharma announced the termination of its clinical development of masofaniten and is evaluating strategic options to maximize shareholder value. The company reported financial results for Q4 and the fiscal year ended September 30, 2024.
Terminated clinical development of masofaniten based on interim analysis.
Evaluating strategic options to maximize shareholder value.
Reported financial results for the fourth quarter and fiscal year ended September 30, 2024.
Withdrew the related IND and CTAs for masofaniten.
Essa Pharma
Essa Pharma
Forward Guidance
ESSA Pharma is currently evaluating and reviewing strategic options focused on maximizing shareholder value and look forward to providing further updates in the near future.